Capricor Therapeutics (CAPR) Stock Statistics & Valuation Metrics

Capricor Therapeutics has a market cap or net worth of $509.64M. The enterprise value is -$27.11B.

Capricor Therapeutics has 45,707,820 shares outstanding. The number of shares has decreased by -2.65% in one year.

Capricor Therapeutics’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -28.48%.

The current PE Ratio of Capricor Therapeutics is -12.01. Capricor Therapeutics’s PEG ratio is <0.01.

In the last 12 months, Capricor Therapeutics had revenue of 22.27M and earned -40.47M in profits. Earnings per share was -1.15.

In the last 12 months, operating cash flow was -6.47B and capital expenditures -896.88M, giving a free cash flow of -7.37B billion.

Capricor Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Capricor Therapeutics upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.

Capricor Therapeutics as a current ratio of 7.77, with Debt / Equity ratio of 0.98%

In the past 12 months, Capricor Therapeutics has paid 0.00 in taxes.

Capricor Therapeutics EV to EBITDA ratio is -11.57, with an EV/FCF ratio of -11.46.

Capricor Therapeutics has $144.78B in cash and marketable securities with $1.25B in debt, giving a net cash position of -$143.53B billion.

Gross margin is 95.78%, with operating margin of -191.13%, and net profit margin of -181.71%.

The average price target for Capricor Therapeutics is $41.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy